LON:POLB Poolbeg Pharma (POLB) Share Price, News & Analysis GBX 4.70 +0.20 (+4.44%) As of 10:34 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Poolbeg Pharma Stock (LON:POLB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Poolbeg Pharma alerts:Sign Up Key Stats Today's Range 4.30▼ 4.7050-Day Range 4.08▼ 4.8052-Week Range 2.40▼ 5.20Volume270,980 shsAverage Volume1.28 million shsMarket Capitalization£33.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. Read More Receive POLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. POLB Stock News HeadlinesTRADING UPDATES: Central Asia Metals cancels share premium account3 hours ago | lse.co.ukPoolbeg Pharma (LON:POLB) Given House Stock Rating at Shore Capital GroupMay 12 at 3:57 AM | americanbankingnews.comIran broke the petrodollar…For 50 years, every barrel of oil settled in dollars - that rule is what made the dollar the world's reserve currency. Iran just broke it, and no sanctions can restore the status quo. Garrett Goggin, CFA, CMT has guided readers to gains of 1,200% over the last two years by tracking gold's rise against a weakening dollar. He's identified four miners positioned to profit through what he calls the last gold bull market of our lifetime.May 12 at 1:00 AM | Golden Portfolio (Ad)Poolbeg Pharma secures Canadian patent for cancer immunotherapy drug POLB 001May 11 at 3:10 PM | finance.yahoo.comPoolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call TranscriptMay 2, 2026 | seekingalpha.comPoolbeg eyes transformative summer with POLB 001 data in prospectApril 28, 2026 | finance.yahoo.comPoolbeg Pharma: Sites ready, data due this summer — and Big Pharma is starting to knockApril 28, 2026 | finance.yahoo.comPoolbeg Pharma eyes partnering deals as cancer immunotherapy trial heads for summer dataApril 28, 2026 | finance.yahoo.comSee More Headlines POLB Stock Analysis - Frequently Asked Questions How have POLB shares performed this year? Poolbeg Pharma's stock was trading at GBX 4 at the beginning of 2026. Since then, POLB shares have increased by 17.4% and is now trading at GBX 4.70. How were Poolbeg Pharma's earnings last quarter? Poolbeg Pharma PLC (LON:POLB) issued its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.94) earnings per share for the quarter. How do I buy shares of Poolbeg Pharma? Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Poolbeg Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP). Company Calendar Last Earnings4/28/2026Today5/12/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:POLB CIKN/A Webwww.poolbegpharma.com Phone44 20 7183 1499FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.50 billion Net MarginsN/A Pretax MarginN/A Return on Equity-55.47% Return on Assets-21.33% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio47.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 2.23 per share Price / Cash Flow2.11 Book ValueGBX 2,489.80 per share Price / Book0.00Miscellaneous Outstanding Shares705,104,000Free FloatN/AMarket Cap£33.14 million OptionableNot Optionable Beta1.82 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (LON:POLB) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersIran broke the petrodollar…For 50 years, every barrel of oil settled in dollars - that rule is what made the dollar the world's reserve c...Golden Portfolio | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayIn 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...Decentralized Masters | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
